Driving Innovation Through Collaboration: The Future of mRNA Therapies
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bern-hard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how ad-vanced fluidics, encapsulation techniques, and a truly collaborative approach are paving the way for potential solid-tumor vaccines now in preclinical trials.
When you think about mRNA-based vaccines, have you ever considered the complex route these microscopic instructions must travel to deliver their life-changing code? This journey, essential for the therapy’s success, lies at the core of pharmaceutical research—where the challenge is to maximize stability and “bioavailability” so that each dose effec-tively reaches its cellular target.
By enclosing mRNA within lipid nanoparticles (LNPs) using sophisticated mixing tech-nologies, scientists can create the next generation of therapies—tailored to each patient’s needs. From prophylactic vaccines to personalized cancer treatments for solid tumors, these breakthroughs promise not only more effective but also safer medical solutions. In this episode, we spotlight FDmiX®, a groundbreaking mixer platform that enables the pre-cise production of LNPs, driving forward the possibility of new, life-saving vaccines in the fight against cancer.
Curious to Learn More?
Join us in this conversation hosted by Martina Ribar Hestericová, featuring Fraunhofer IPK’s Christoph Hein, FDX Fluid Dynamix’s Bernhard Bobusch, and Lonza’s Sönke Stocker, as they unveil how FDmiX® and mRNA encapsulation could revolutionize the development of solid-tumor vaccines and other cutting-edge therapies.
KEY TERMS:
Smart capsule In this episode, the term smart capsule is used broadly to describe oral delivery systems that do more than passively release medication. While BioGrail’s CEO Karsten Lindhart notes it’s not a term they typically use, their capsule fits the category — and exceeds it — by incorporating a spring-loaded mechanism that actively delivers biologics into the stomach lining, achieving injection-like bioavailability without the needle.
Capsule sizes 00 and 0 Capsule size standards refer to the physical dimensions of pharmaceutical capsules. Size 00 is a large capsule, often used for adult dosages, while size 0 is slightly smaller. BioGrail is exploring these sizes, including smaller versions for pediatric patients.
Bioavailability Bioavailability measures how much of a drug enters the bloodstream and becomes available at the intended site of action. Biograil’s oral capsule achieves levels of bioavailability similar to subcutaneous injections, marking a significant advancement for oral biologics.
Insertion element is a sensation or action where stomach contents flow back up into the esophagus, contributing to discomfort and heartburn.
Compliance Also called adherence, compliance refers to whether patients take their medication as prescribed. Easier, less invasive administration methods like oral capsules can significantly increase patient compliance—especially in chronic conditions requiring frequent dosing.